inc la jolla ca base
biopharma compani oper lean busi
model invest royalti asset technolog
excipi use pharma product run small
reason report
price chang estim chang analysi
report solid result increas guidanc
today given visibl ep upsid nv
year base nt momentum key commerci program
combin diversifi play biotech provid
explan addit omniab remain valuabl asset
increas attract product move into/through
clinic trial final believ investor remain tune capit
target result favor nt/lt momentum
increas pt see reason
notew dbemostaggressiveinthisnameonpullback
revis guidanc provid management
kyproli revenu quarter mil
highlight mil order clinic trial
thevalueoftheasset-upfrontforaccess royaltiesstillinplay
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
except per share data
good sold
amort intang
decrease/ increas conting liabil
 loss vike
net loss attribut nci
net incom attribut
forma ep exclud non-recur expens period neg ep basic share outstand use
compani report stephen inc estim
thousand except share data
clinic materi sale
commerci materi sale
licens fee revenu
percent sale analysi
royalti revenu recogn one-quart lag prior exampl royalti revenu base partner drug sale
compani report stephen inc estim
thousand except share data perscript unit
promacta royalti revenu due
mil revenu
mil mil revenu
mil mil revenu
mil bil revenu
bil revenu
tier promacta royalti due
royalti mil revenu
royalti mil mil revenu
royalti mil mil revenu
royalti mil bil revenu
royalti bil revenu
promacta royalti revenu due
total kyproli royalti revenu due
mil revenu
mil mil revenu
mil mil revenu
mil revenu
tier kyproli royalti due
royalti mil revenu
royalti mil mil revenu
royalti mil mil revenu
royalti mil revenu
kyproli royalti revenu due
royalti evomela sale
evomela royalti revenu due
royalti net carnexiv sale
carnexiv royalti revenu due
cormatrix royalti revenu due
royalti revenu due
total royalti revenu due
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
